Get MindMed Updates:
We believe in working with leading institutions and researchers to get to more reliable insights faster, together.
MindMed proudly partners with the Liechti Lab of Professor Dr. Matthias Liechti, the world-leading psychedelics pharmacology and clinical research group at University Hospital Basel in Switzerland. This collaboration includes the exclusive rights to data, compounds, and patents associated with the research on lysergic acid diethylamide (LSD) and other psychedelic compounds.
Over the past decade we have amassed the largest collection of clinical trials around LSD; we have been studying the pharmacology and potential medical uses of LSD and other psychedelics for many years in the laboratory, in patients, and in healthy volunteers.”
MindMed Discover is a wholly owned subsidiary, based in Switzerland and directed by Dr Miri Halperin Wernli. MindMed Discover exists to do just that: discover, acting as the hub for psychedelic R&D central to our global operations & collaborations.
MindMed is funding the launch of a clinical training program at NYU Langone Health that aims to facilitate the recruitment and training of more psychiatrists and clinical investigators in delivering psychedelic assisted therapies and psychedelic inspired medicines. In preparation for future deployment of these medicines, it is imperative to get psychedelic substances in front of clinical researchers and give them the resources they need to help clarify the path forward.
The NYU Langone Health Psychedelic Medicine Research Training Program will provide support, training, mentorship, and research funding necessary and will be managed by Principal Investigator Michael Bogenschutz, M.D., an expert in clinical trials research and the primary investigator leading the effort for approval of psilocybin-assisted psychotherapy for Alcohol Use Disorder by the FDA. The program will be directed by Stephen Ross, M.D., a world leader in advancing research on psychedelic medicine and a prominent addiction psychiatrist.
MindMed is collaborating with Maastricht University in the Netherlands to undertake a Phase 2a clinical trial for microdosing LSD for adult ADHD. The proof-of-concept study is planned to take place at two trial sites, including Maastricht University. The principal investigator of the study is Kim Kuypers, one of the world’s top psychedelics microdosing clinical researchers. The trial is scheduled to begin at the end of 2020.
Anyone who has ever lived with a mental health disorder understands how complex and intractable they can be . This means for many patients, mental health care treatment must work across their different conditions.
At MindMed, we believe the interconnectedness of these mental health disorders is not just a challenge — it is an opportunity. We’re creating a new paradigm for mental health care that incorporates both psychedelic-assisted therapy and non-hallucinogenic take-home medicines to help patients overcome and break through.
With this innovative treatment paradigm, we are looking to bring the participants outside the bounds of their everyday perceptions, facilitating new states of consciousness and flexibility. Combining MDMA and LSD may enhance the positive effects of LSD by inducing a positive psychological state with MDMA which is an empathogen to help counteract some known negative or less positive aspects of LSD.
Mental health is not one-size-fits-all, nor should treatment be. Our comprehensive toolset includes the tools necessary to optimize the patient experience.
Your brain is unique, your treament should be too.
Technologies and analytics that seek to personalize psychedelic therapy experiences for a specific patient are imperative to the patient experience. This technology aims to optimize the dosing of MDMA, LSD and other psychedelics based on a patient’s profile. The R&D is taking place in collaboration with the University Hospital Basel’s Liechti Lab, the leading research center focused on the pharmacology of psychedelic substances.
Neutralizer technology was designed to shorten and stop the effects of an LSD trip during a therapy session and may help reduce the acute effects of a psychedelic drug and help shorten the hallucinogenic effects if or when required by a patient or medical professional.
This discovery, when further developed, may act as the ‘off-switch’ to an LSD trip.
MindMed will continue to innovate, develop and patent its own technologies that integrate psychedelic compounds and enhance the therapy potential, and is committed to equipping medical professionals with the resources & technology to improve patient experience and patient outcomes.